All In Biotech

NDA 017001 · Bausch

Ancobon

Flucytosine · Oral · Nucleoside Analog Antifungal

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1971

Nov 26, 1971

Approved uses

1

Original approval plus efficacy supplements

Registered trials

46

7 Phase 3, 3 recruiting

FAERS reports

1,418

1,362 serious, 491 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These instructions should be thoroughly reviewed before administration of ANCOBON.

What it is approved for

From the label in effect Feb 2, 2022.

INDICATIONS AND USAGE ANCOBON is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. ANCOBON should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to ANCOBON (see MICROBIOLOGY ).

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 26, 1971 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • ANCOBON · FLUCYTOSINE 500MG · CAPSULE, ORAL · Prescription · TE AB
  • ANCOBON · FLUCYTOSINE 250MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Flucytosine" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective467
  • off label use140
  • immune reconstitution inflammatory syndrome105
  • meningitis cryptococcal98
  • acute kidney injury88
  • renal impairment79
  • condition aggravated76
  • cryptococcosis66
  • disseminated cryptococcosis66
  • drug interaction58
  • headache58
  • pyrexia58

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
20059
20063
200712
200822
200920
201024
201112
201223
201319
201428
201530
201640
201764
201860
201989
2020120
2021116
2022124
2023127
2024138
2025181
2026145

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 102 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.